Aim To determine the role of endothelin (ET)-1 in predicting hepatopulmonary syndrome (HPS) in patients with liver cirrhosis. Methods A cross sectional study involving 80 liver cirrhosis patients aged 18 years or older was conducted in Adam Malik General Hospital Medan, Indonesia between July 2017 and June 2018. HPS diagnosis was confirmed from the presence of liver cirrhosis, abnormal oxygenation, and intrapulmonary vascular dilatations (IPVD). ET-1 level was measured from serum sample using ELI-SA method. Patients with coexisting primary pulmonary pathology and intrinsic heart disease were active smokers, and those who declined to participate were excluded. Statistical analysis was conducted at 95% confidence interval. p<0.05 was considered significant. Results Majority the patients were male (56.3%) and had higher educational background (62.5%). Mean age of the patients was 51.3 (SD=12.6) years. The prevalence of HPS was 21.2%. The patients with HPS had higher ET-1 level compared to those without HPS (p<0.001). The patients with hepatic encephalopathy had 2.917 times higher risk for suffering from HPS, while the patients with Child Pugh score A had lower risk (0.738 times) for having HPS compared to subjects with Child Pugh score B and C. ET-1 level >187.5 mg/L had sensitivity and specificity for predicting HPS in subjects with liver cirrhosis of 82.35% and 81.25%, respectively. Conclusion ET-1 could be used as a promising marker for HPS in patients with liver cirrhosis. ET-1 level of >187.5 mg/l had a good accuracy in predicting HPS in liver cirrhosis patient.
Li B, Zhang C, Zhan Y. Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis. Can J Gastroenterol Hepatol. 2018;2784537.
2.
Patasik Y, Waleleng B, Wantania F. Profil pasien sirosis hati yang dirawat inap di RSUP Prof. Dr. R. D. Kandou Manado periode Agustus 2012-Agustus 2014 (Profile of patients with liver cirrhosis admitted in Prof. Dr. R. D. Kandou general hospital Manado between. eCl. :342–7.
3.
Ratib S, West J, Fleming K. Liver cirrhosis in England-an observational study: are we measuring its burden occurrence correctly? BMJ Open. 2017;13752.
4.
Elvira D. Diagnosis dan tatalaksana hepatopulmonary syndrome (Diagnosis and management of hepatopulmonary syndrome. MKA. 2015;57–65.
5.
Kalista K, Lesmana C, Sulaiman A, Gani R, Hasan I. Clinical profile of cirrhotic patient with esophageal varices who undergone band ligation in Cipto Mangunkusumo Hospital. Jurnal Penyakit Dalam Indonesia. 2019;36–41.
6.
Soulaidopoulos S, Cholongitas E, Giannakoulas G, Vlachou M, Goulis I. Review article: update on current and emergent data on hepatopulmonary syndrome. World J Gastroenterol. 2018;1285–98.
7.
Davenport A, Hyndman K, Dhaun N, Southan C, Kohan D, Pollock J, et al. Pharmacol Rev. 2016;357–418.
8.
Voiosu A, Daha I, Voiosu T, Mateescu B, Dan G, Baicus C, et al. Prevalence and impact on survival of hepatopulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic patients. Liver Int. 2015;2547–55.
9.
Alam I, Bass N, Bacchetti P, Gee L, Rockey D. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol. 2000;199–203.
10.
Kaffarnik M, Ahmadi N, Lock J, Wuensch T, Pratschke J, Stockmann M, et al. Correlation between plasma endothelin-1 levels and severity of septic liver failure quantified by maximal liver function capacity (LiMAx test). A prospective study. PLoS One. 2017;178237.
11.
Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol. 2005;100–7.
12.
Koch D, Bogatkevich G, Ramshesh V, Lemasters J, Uflacker R, Reuben. Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci. 2012;516–23.
13.
He J, Yi B, Chen Y, Huang Q, Wang H, Lu K, et al. The ET-1-mediated carbonylation and degradation of ANXA1 induce inflammatory phenotype and proliferation of pulmonary artery smooth muscle cells in HPS. PLoS One. 2017;175443.
14.
Grebes A, Moller S, Gullberg V, Henriksen J. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology. 1995;735–9.
15.
Koch D, Bogatkevich G, Ramshesh V, Lemasters J, Uflacker R, Reuben. Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci. 2012;516–23.
16.
Nishiyama S, Zhao J, Wray D, Richardson R. Vascular function and endothelin-1: tipping the balance between vasodilatation and vasoconstriction. J Appl Physiol. 2017;354–60.
17.
Kamath P, Carpenter H, Lloyd R, Mckusick M, Steers J, Nagorney D, et al. Hepatic localization of entothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl. 2000;596–602.
18.
Mousa ARA, Abdelsalam N, Abdelwahab M, Tawfik A, Tawfik M, Hasan A, et al. Endothelin-1/nitric oxide ratio as a predictive factor of response to therapy with terlipressin and albumin in patients with type-1 hepatorenal syndrome. Front Pharmacol. 2020;9.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
